Ignite Creation Date:
2024-07-17 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06463665
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-06-11
Brief Title:
Efficacy Safety of Olvimulogene Nanivacirepvec Platinum-doublet Physicians Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Sponsor:
Organization:
Genelux Corporation